Literature DB >> 22274414

Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Cheol-In Kang, So Yeon Park, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22274414     DOI： 10.1016/j.jinf.2012.01.008

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  15 in total

1.  Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.

Authors:  J-H Ko; N R Lee; E-J Joo; S-Y Moon; J-K Choi; D A Park; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-25       Impact factor: 3.267

Review 2.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 3.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

4.  In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.

Authors:  Min Kyeong Cha; Cheol-In Kang; So Hyun Kim; Sun Young Cho; Young Eun Ha; Yu Mi Wi; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

5.  Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.

Authors:  Pranita D Tamma; Maria Virginia Villegas
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase-Producing Enterobacterales Urinary Tract Infections.

Authors:  Daniel T Anderson; Benjamin Albrecht; K Ashley Jones; Jesse T Jacob; Mary Elizabeth Sexton; Zanthia Wiley; William C Dube; Benjamin Lee; Sujit Suchindran
Journal:  Open Forum Infect Dis       Date:  2022-02-14       Impact factor: 3.835

7.  Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A retrospective cohort study.

Authors:  Sun Tae Ahn; Da Eun Han; Dong Hyun Lee; Jong Wook Kim; Hong Seok Park; Du Geon Moon; Mi Mi Oh
Journal:  Investig Clin Urol       Date:  2021-05

8.  Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Tat Ming Ng; Wendy X Khong; Patrick N A Harris; Partha P De; Angela Chow; Paul A Tambyah; David C Lye
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

9.  Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital.

Authors:  Shinwon Lee; Seung Woo Han; Kun Woo Kim; Do Young Song; Ki Tae Kwon
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

Review 10.  Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.

Authors:  Allison M Gibble; Alan E Gross; Angela M Huang
Journal:  Antibiotics (Basel)       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.